Sinemet (Carbidopa/Levodopa)
Dopaminergic combination therapy for Parkinson's disease
Sinemet is a prescription combination medication containing carbidopa and levodopa, used as the gold-standard treatment for Parkinson's disease. Levodopa is converted to dopamine in the brain, alleviating motor symptoms such as tremor, rigidity, and bradykinesia. Carbidopa prevents peripheral breakdown of levodopa, increasing its effectiveness and reducing side effects like nausea. This guide covers uses, dosage, side effects, drug interactions, and important safety information based on international clinical guidelines.
Quick Facts
Key Takeaways
- Sinemet combines levodopa (converted to dopamine in the brain) with carbidopa (which prevents peripheral breakdown), making it the cornerstone treatment for Parkinson's disease motor symptoms.
- Never stop Sinemet abruptly — sudden discontinuation can trigger a dangerous condition resembling neuroleptic malignant syndrome with high fever, rigidity, and altered consciousness.
- Common side effects include nausea, involuntary movements (dyskinesia), dizziness on standing, and mental changes such as confusion or hallucinations, which are generally dose-dependent.
- Non-selective MAO inhibitors must be discontinued at least 14 days before starting Sinemet due to the risk of hypertensive crisis.
- Patients and caregivers should watch for impulse control disorders (gambling, compulsive shopping, hypersexuality, binge eating) and report any changes to the prescribing physician promptly.
What Is Sinemet and What Is It Used For?
Sinemet contains two active ingredients that work together to manage Parkinson's disease. Levodopa is a precursor to dopamine, a neurotransmitter essential for coordinating smooth, controlled movements. In Parkinson's disease, the dopamine-producing neurons in the substantia nigra of the brain progressively degenerate, leading to a significant reduction in dopamine levels. This deficit manifests as the cardinal motor symptoms: resting tremor, muscular rigidity, bradykinesia (slowness of movement), and postural instability.
When taken orally, levodopa crosses the blood-brain barrier and is converted into dopamine by the enzyme aromatic L-amino acid decarboxylase (AADC). This conversion replenishes the depleted dopamine stores in the striatum, thereby alleviating the motor symptoms of the disease. Levodopa has been the most effective pharmacological treatment for Parkinson's disease since its introduction in the late 1960s and remains the gold standard of therapy according to all major international guidelines, including those from the Movement Disorder Society (MDS), the National Institute for Health and Care Excellence (NICE), and the American Academy of Neurology (AAN).
Carbidopa is a peripheral decarboxylase inhibitor that plays a critical supporting role. Without carbidopa, approximately 95% of orally administered levodopa would be converted to dopamine in the peripheral tissues before it could reach the brain. This peripheral conversion not only wastes the active drug but also produces significant side effects, particularly nausea and vomiting. Carbidopa does not cross the blood-brain barrier, so it selectively inhibits the peripheral decarboxylation of levodopa, allowing a much greater proportion of the dose to reach the central nervous system. This means that lower doses of levodopa can be used while achieving better therapeutic effects and fewer gastrointestinal side effects.
Sinemet is available in two standard strengths: 12.5 mg carbidopa / 50 mg levodopa and 25 mg carbidopa / 100 mg levodopa. The choice of strength and total daily dose depends on the individual patient's needs, disease severity, and response to treatment. Your doctor will carefully titrate the dose to find the optimal balance between symptom control and side effects.
Levodopa/carbidopa is included on the World Health Organization's Model List of Essential Medicines, recognising it as one of the most efficacious, safe, and cost-effective medicines needed in any health system. It is considered indispensable for the management of Parkinson's disease worldwide.
What Should You Know Before Taking Sinemet?
Several important medical and pharmacological factors must be considered before initiating therapy with Sinemet. A thorough understanding of contraindications, warnings, and precautions will help ensure the safest and most effective use of this medication. Always provide your healthcare provider with a complete medical history and a list of all medications you are currently taking, including over-the-counter products and dietary supplements.
Contraindications
You must not take Sinemet if any of the following conditions apply to you:
- Allergy to carbidopa, levodopa, or any excipient — If you have a known hypersensitivity to either active ingredient or any of the inactive components (listed in the Ingredients section below), you should not take this medication.
- Narrow-angle glaucoma — Sinemet is contraindicated in patients with narrow-angle (closed-angle) glaucoma due to the risk of increasing intraocular pressure. Open-angle glaucoma patients may use Sinemet under careful ophthalmological monitoring.
- Recent MAO inhibitor use — Non-selective monoamine oxidase (MAO) inhibitors must be discontinued at least 14 days before starting Sinemet. Concurrent use can cause dangerous hypertensive crisis. Selective MAO-B inhibitors (such as selegiline or rasagiline) at recommended doses are generally considered safe to combine with Sinemet.
- Severe cardiovascular disease — Patients with severe heart conditions, including recent myocardial infarction with residual arrhythmias, should not use Sinemet without careful risk-benefit assessment.
- Severe hepatic or renal impairment — Significant liver or kidney disease may alter drug metabolism and clearance.
- Pheochromocytoma — This adrenal gland tumour can cause hypertensive attacks that may be exacerbated by levodopa.
- Psychosis — Active psychotic disorders are a contraindication due to the dopaminergic nature of levodopa therapy.
Warnings and Precautions
Before starting and during treatment with Sinemet, your doctor should be made aware of the following conditions and risk factors:
- History of myocardial infarction or cardiac arrhythmias — Levodopa may cause cardiac irregularities and should be used with caution in patients with a history of heart disease. Regular cardiac monitoring may be advisable.
- Pulmonary disease or bronchial asthma — Patients with severe respiratory conditions require careful monitoring during treatment.
- Endocrine disorders — Conditions such as Cushing's syndrome or hyperthyroidism may interact with dopaminergic therapy.
- Psychiatric history — Patients with a history of depression, psychosis, or other mental health conditions may experience worsening symptoms. Depression with suicidal ideation has been reported in some patients taking levodopa/carbidopa.
- Peptic ulcer disease — Levodopa may activate peptic ulcers. Patients with a history of gastrointestinal bleeding should be monitored closely.
- History of seizures — Convulsions have been reported rarely. Use with caution in patients with epilepsy.
- Suspicious skin lesions or history of melanoma — Some epidemiological studies have suggested a possible association between Parkinson's disease and melanoma (independent of medication use). Patients should undergo regular dermatological examinations.
Sinemet and other dopaminergic medications can cause impulse control disorders, including pathological gambling, compulsive shopping, binge eating, and hypersexuality. These behaviours may not be recognised by the patient as abnormal. Family members and caregivers play an essential role in monitoring for these changes. If such behaviours develop, contact the prescribing physician immediately for dose adjustment or treatment modification.
Never discontinue Sinemet suddenly without medical supervision. Abrupt withdrawal can cause a potentially life-threatening condition resembling neuroleptic malignant syndrome, characterised by high fever, severe muscular rigidity, altered consciousness, and autonomic instability. Any dose changes should be made gradually under medical guidance.
Pregnancy and Breastfeeding
There is limited clinical experience with the use of Sinemet during pregnancy. Animal studies have shown potential adverse effects on foetal development. Sinemet should only be used during pregnancy when the potential benefit clearly justifies the potential risk to the foetus. Women of childbearing potential should discuss contraception with their healthcare provider.
It is not known whether carbidopa or levodopa is excreted in human breast milk. Due to the pharmacological activity of these substances and the potential for adverse effects in the nursing infant, a decision must be made whether to discontinue breastfeeding or discontinue the medication, taking into account the importance of the drug to the mother.
Children and Adolescents
Sinemet should not be given to children or adolescents under 18 years of age. There is insufficient clinical experience with carbidopa/levodopa in the paediatric population, and the safety and efficacy have not been established in this age group.
Driving and Operating Machinery
Sinemet may cause somnolence (excessive drowsiness) and episodes of sudden onset of sleep. Patients who experience these effects must refrain from driving vehicles or operating heavy machinery until the episodes have resolved. This effect can occur without any prior warning signs and may persist throughout treatment. Patients should be specifically warned about this risk at the start of therapy and at each dose adjustment.
How Does Sinemet Interact with Other Drugs?
Drug interactions with Sinemet can be clinically significant and may either reduce the effectiveness of the medication or increase the risk of adverse effects. The following table summarises the most important interactions. Always discuss all your medications with your healthcare provider before starting or stopping any treatment.
Major Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Non-selective MAO inhibitors (phenelzine, tranylcypromine) | Risk of hypertensive crisis with severe blood pressure elevation | Discontinue at least 14 days before starting Sinemet |
| Antipsychotics (haloperidol, risperidone, chlorpromazine) | Block dopamine receptors, reducing Sinemet's effectiveness | Avoid conventional antipsychotics; quetiapine or clozapine may be alternatives |
| Isoniazid (tuberculosis treatment) | May reduce the therapeutic effect of levodopa | Monitor for reduced efficacy; dose adjustment may be needed |
| Phenytoin (anti-epileptic) | May reduce the effect of levodopa and worsen Parkinsonian symptoms | Monitor closely; consider alternative anti-epileptic drugs |
Other Notable Interactions
| Interacting Drug | Effect | Recommendation |
|---|---|---|
| Iron supplements | Chelation reduces levodopa absorption by up to 50% | Take at least 2 hours apart from Sinemet |
| Antihypertensives | Enhanced blood pressure lowering; risk of symptomatic orthostatic hypotension | Monitor blood pressure, especially when standing; adjust antihypertensive dose if needed |
| High-protein meals | Amino acids compete with levodopa for intestinal absorption and brain transport | Take Sinemet 30–60 minutes before meals or on an empty stomach for optimal absorption |
| Metoclopramide (anti-nausea) | Dopamine receptor blockade may reduce Sinemet's effectiveness | Use domperidone instead if an antiemetic is needed |
| Tricyclic antidepressants | Rare reports of hypertension and dyskinesia | Use with caution; monitor blood pressure |
Sinemet can affect certain laboratory test results. It may cause false-positive results for urinary ketones and white blood cells in dipstick tests. Blood glucose levels and some liver function tests may appear elevated. It can also cause darkened urine, which is harmless. Inform your laboratory that you are taking carbidopa/levodopa so that results can be interpreted correctly.
What Is the Correct Dosage of Sinemet?
The dosage of Sinemet must be determined individually by your doctor, who will adjust the dose based on your symptoms, response to treatment, and tolerance. There is no universal "correct" dose — rather, the goal is to find the lowest effective dose that provides adequate symptom control with acceptable side effects. The following information provides general dosage guidance based on international clinical practice; however, always follow your doctor's specific instructions.
Adults
Initial Therapy (Levodopa-Naive Patients)
For patients who have not previously taken levodopa, treatment is typically initiated with one tablet of Sinemet 25/100 mg three times daily. The dose may be increased by one tablet every one to two days until a satisfactory clinical response is achieved. Most patients require between 75 mg and 200 mg of carbidopa daily to achieve optimal inhibition of peripheral decarboxylase. The maximum recommended daily dose of levodopa is generally 800 mg, though some patients may require more under specialist supervision.
Switching from Levodopa Alone
Patients already taking levodopa should discontinue levodopa at least 12 hours before starting Sinemet. The initial dose of Sinemet should provide approximately 20% of the previous levodopa daily dose. Patients previously requiring more than 1500 mg of levodopa daily should start with Sinemet 25/250 mg three to four times daily.
Maintenance Therapy
Optimal maintenance doses vary widely between patients. Doses are typically taken 3–6 times daily, with intervals adjusted to maximise "on" time and minimise motor fluctuations. Substitution therapy or additional doses may be added based on clinical response. Patients experiencing wearing-off phenomena may benefit from more frequent, smaller doses or the addition of a COMT inhibitor or MAO-B inhibitor as adjunctive therapy.
Elderly Patients
Elderly patients may be more sensitive to the effects of levodopa. Treatment should start at the lower end of the dosage range and be titrated more slowly. Orthostatic hypotension (dizziness on standing) and neuropsychiatric side effects such as confusion and hallucinations are more common in older adults. Regular monitoring and careful dose adjustments are essential in this population.
Children
Sinemet is not recommended for use in children and adolescents under 18 years of age due to insufficient clinical data on safety and efficacy in this population.
Missed Dose
If you forget to take a dose, take it as soon as you remember. However, if it is almost time for your next scheduled dose, skip the missed dose and continue with your regular dosing schedule. Do not take a double dose to make up for a missed one. If you frequently miss doses, consider setting alarms or using a pill organiser to help maintain a consistent schedule. Consistency in timing is important for maintaining stable symptom control throughout the day.
Overdose
If you have taken more Sinemet than prescribed, or if a child has accidentally ingested the medication, seek emergency medical attention immediately. Symptoms of overdose may include severe nausea and vomiting, cardiac arrhythmias, agitation, and confusion. There is no specific antidote for carbidopa/levodopa overdose; treatment is supportive and symptomatic. Contact your local poison control centre or emergency department for guidance.
If you need to split a tablet to help with swallowing, ensure you take all fragments as the complete dose. If a tablet breaks apart when removing it from the blister pack, verify that you have all pieces. Taking only a partial dose may lead to worsening of Parkinson's symptoms. If pieces are missing, discard the broken tablet and use a new one.
What Are the Side Effects of Sinemet?
Side effects of Sinemet are classified below by their frequency of occurrence. Many of these effects are related to the dopaminergic action of levodopa and are dose-dependent, meaning they may improve with dosage reduction. It is important to report any new or worsening symptoms to your healthcare provider, as adjustments to your treatment can often mitigate these effects.
Very Common
May affect more than 1 in 10 people
- Urinary tract infections
Common
May affect up to 1 in 10 people
- Dyskinesia (involuntary, uncontrolled movements)
- Temporary slowing of movements
- Dystonia (sustained muscle contractions)
- Dizziness, especially upon standing (orthostatic hypotension)
- Loss of appetite (anorexia)
- Nausea and vomiting
- Bitter taste in the mouth
- Palpitations and cardiac arrhythmias
- Mental changes: anxiety, confusion, memory impairment, euphoria, paranoid ideation, hallucinations, insomnia
- Depression, with or without suicidal thoughts
Uncommon
May affect up to 1 in 100 people
- Dry mouth or increased salivation
- Difficulty swallowing (dysphagia)
- Diarrhoea, constipation, or flatulence
- Abdominal pain and discomfort
- Dark-coloured urine (harmless)
- Elevated blood pressure or oedema
- Fainting (syncope) or feeling faint
- Hot flushes
- Weight gain or weight loss
- Muscle cramps and twitching
- Hoarseness and altered breathing patterns
- Fatigue, weakness, and headache
- Agitation and nightmares
Rare
May affect up to 1 in 1,000 people
- Bruxism (teeth grinding, particularly during sleep)
- Disorientation, hiccups, heartburn
- Dark saliva, burning sensation on the tongue
- Gastrointestinal ulceration and bleeding
- Superficial vein inflammation (phlebitis)
- Urticaria (hives), skin rash, pruritus (itching), hair loss
- Angioedema (swelling of face, lips, tongue, or throat)
- Eye disturbances: blurred vision, double vision, pupil dilation, eyelid twitching, drooping eyelid, activation of Horner's syndrome
- Anaemia and other blood count abnormalities
- Numbness, tingling (paraesthesia), seizures
- Neuroleptic malignant-like syndrome (high fever, rigid muscles, altered mental status)
- Jaw muscle spasm (trismus)
- Urinary retention or incontinence
- Increased libido, priapism (prolonged painful erection)
- Dyspnoea (shortness of breath), chest pain
- Excessive or discoloured sweating
- Somnolence (excessive drowsiness), sudden sleep attacks
- Activation of melanoma
Not Known
Frequency cannot be estimated from available data
- Dopaminergic dysregulation syndrome: compulsive craving for higher doses beyond what is needed for motor symptom control
- Impulse control disorders: pathological gambling, compulsive shopping, binge eating, hypersexuality
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance. Healthcare professionals and patients are encouraged to report adverse reactions to their national pharmacovigilance authority (e.g., the FDA MedWatch programme in the USA, the Yellow Card Scheme in the UK, or the EMA EudraVigilance system in the EU).
How Should You Store Sinemet?
Proper storage of your medication ensures that it remains effective and safe throughout its shelf life. Follow these guidelines for storing Sinemet:
- Temperature: Store at room temperature (below 25°C / 77°F). No special temperature-controlled storage is required.
- Moisture: Keep the tablets in their original packaging (blister pack or container) to protect from moisture. Do not store in bathrooms or other humid environments.
- Light: Protect from direct sunlight and excessive heat.
- Children: Keep out of sight and reach of children at all times.
- Expiry date: Do not use Sinemet after the expiry date printed on the carton and blister/label. The expiry date refers to the last day of that month.
Do not dispose of medicines via household waste or down the drain. Ask your pharmacist about proper medication disposal programmes in your area. These measures help protect the environment and prevent accidental exposure.
What Does Sinemet Contain?
Active Ingredients
| Strength | Carbidopa | Levodopa |
|---|---|---|
| Sinemet 12.5/50 | 12.5 mg | 50 mg |
| Sinemet 25/100 | 25 mg | 100 mg |
Inactive Ingredients (Excipients)
The inactive ingredients in Sinemet tablets are: microcrystalline cellulose, pregelatinized starch, maize starch (corn starch), magnesium stearate, and quinoline yellow (E104) as a colouring agent.
Tablet Appearance
- Sinemet 12.5/50 mg: Yellow, oval tablet, engraved "520" on one side and plain on the other. Tablet dimensions: 9.5 mm x 5 mm. Supplied in blister packs of 100 tablets.
- Sinemet 25/100 mg: Yellow, oval tablet, engraved "650" on one side and plain on the other. Tablet dimensions: 12.7 mm x 7.1 mm. Supplied in plastic bottles of 100 tablets.
Manufacturer
Sinemet is manufactured by Merck Sharp & Dohme B.V. (Haarlem, Netherlands) and N.V. Organon (Oss, Netherlands). The marketing authorisation is held by N.V. Organon, Kloosterstraat 6, 5349 AB Oss, Netherlands.
Frequently Asked Questions About Sinemet
Sinemet is a combination of carbidopa and levodopa used to treat Parkinson's disease. Levodopa is converted to dopamine in the brain, helping to reduce symptoms such as tremor, muscle stiffness, slow movement, and balance difficulties. Carbidopa prevents the breakdown of levodopa outside the brain, making the treatment more effective and reducing side effects like nausea.
The most common side effects of Sinemet include nausea, vomiting, loss of appetite, dizziness (especially when standing up quickly), involuntary movements (dyskinesia), mental changes such as confusion or hallucinations, and dark-coloured urine. Urinary tract infections are also very common. Most side effects are dose-dependent and may improve with dosage adjustments by your doctor.
No, you should never stop taking Sinemet suddenly without medical supervision. Abrupt discontinuation can cause a dangerous condition similar to neuroleptic malignant syndrome, with symptoms including high fever, muscle rigidity, and altered consciousness. Always consult your doctor before making any changes to your Sinemet dosage. Any dose reductions should be done gradually.
Yes, Sinemet has several important drug interactions. Non-selective MAO inhibitors must be stopped at least 2 weeks before starting Sinemet. Antipsychotic medications can reduce its effectiveness. Iron supplements can decrease absorption and should be taken at least 2 hours apart. High-protein meals may also reduce absorption. Always inform your doctor about all medications you are taking, including over-the-counter products and supplements.
Yes, Sinemet and other dopaminergic medications can cause impulse control disorders in some patients. These may include pathological gambling, compulsive shopping, binge eating, and increased sexual urges. These behaviours may not be recognised by the patient as abnormal. If you or your family notice any unusual compulsive behaviours, inform your doctor immediately so that treatment can be adjusted.
For optimal absorption, Sinemet is best taken 30 to 60 minutes before meals or on an empty stomach. High-protein foods can interfere with levodopa absorption because amino acids compete with levodopa for transport across the intestinal wall and the blood-brain barrier. However, if nausea is a problem, taking it with a small, low-protein snack such as crackers may help. Discuss the best approach with your doctor.
References
- European Medicines Agency (EMA). Sinemet — Summary of Product Characteristics. Available from the EMA product information database. Last updated 2025.
- U.S. Food and Drug Administration (FDA). Sinemet (carbidopa-levodopa) Prescribing Information. FDA Approved Drug Products. Revised 2024.
- National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults. NICE guideline [NG71]. Updated 2024.
- Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018;33(8):1248–1266. doi:10.1002/mds.27372
- World Health Organization (WHO). Model List of Essential Medicines — 23rd list (2023). Geneva: WHO; 2023.
- Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA. 2014;311(16):1670–1683. doi:10.1001/jama.2014.3654
- British National Formulary (BNF). Co-careldopa. National Institute for Health and Care Excellence. Last updated January 2026.
- Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020;323(6):548–560. doi:10.1001/jama.2019.22360
- Weintraub D, David AS, Evans AH, et al. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord. 2015;30(2):121–127. doi:10.1002/mds.26016
- Pharmacovigilance Risk Assessment Committee (PRAC). Levodopa-containing medicinal products — periodic safety update reports assessment. EMA/PRAC. 2024.
About Our Medical Editorial Team
Medical Content
Written by the iMedic Medical Editorial Team, comprising licensed physicians with specialist training in neurology, clinical pharmacology, and movement disorders. Our authors hold board certifications and maintain active clinical practice alongside their editorial work.
Medical Review
Reviewed by the iMedic Medical Review Board, an independent panel of specialist physicians who verify all medical content against current international guidelines (WHO, EMA, FDA, NICE, MDS-ES) and the GRADE evidence framework. Every article undergoes rigorous fact-checking before publication.
Editorial Independence: iMedic receives no commercial funding from pharmaceutical companies. All content is created independently and is free from advertising influence. Our complete editorial standards are available at Editorial Standards.